From the Archives: The Promise of Ketamine

promiseofketamine.jpgThis month, the FDA approved the use of esketamine, a nasal spray based on the old anesthetic and once-popular club drug ketamine, to treat people with severe depression that has not responded to other treatments. It’s costly and entails visiting the doctor for four hours a week for four weeks, but it’s the first treatment in decades that works in a new way in the brain. That means it might reach the large number of people with depression who are not helped by drugs that target other brain functions.

Last March, Ronald S. Duman, Ph.D., wrote for Cerebrum on “The Dazzling Promise of Ketamine,” exploring how the drug was validated as an antidepressant, how it works, and what it could mean for development of other drugs: Continue reading

%d bloggers like this: